Tyler, a real patient with narcolepsy on LUMRYZ,
more awake to study after class
Tyler was compensated by Alkermes.
Individual results may vary.
Extended-release LUMRYZ is dosed once at bedtime1
Its innovative oxybate formula delivers treatment throughout your patient’s nocturnal sleep period1,2
Patients take 1 packet at bedtime. 1
LUMRYZ is available in the following dose strengths: 4.5, 6, 7.5, and 9 grams.1
Each premeasured packet contains a full therapeutic dose, supporting consistent dosing.1,3
LUMRYZ dosing information
Once-at-bedtime, premeasured packets contain your patient’s full therapeutic dose, supporting consistent dosing1,3
Doses are available in 4.5 g, 6 g, 7.5 g, and 9 g packets.1
LUMRYZ is taken orally as a single dose at bedtime1
- Mix 1 premeasured packet with water1,4*
- If desired, patients can include a calorie-free drink mix or flavored water enhancer, such as Crystal Lite or Mio Flavored Water Enhancer
Each dose contains a blend of immediate- and controlled-release granules1,2,5
- Shake for 60 seconds—expect the granules to not fully dissolve in water* and have a gritty texture with a salty taste5
LUMRYZ should be taken at least 2 hours after eating and when in bed1
- Patients may fall asleep within 5 to 15 minutes of taking their dose without feeling drowsy
- Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use) for full administration instructions.
- *Do not use hot water.4
These instructions are not complete. Download Instructions for Use for complete administration directions.
Information to share with patients as they begin treatment
Support successful patient startsTyler is a real patient, compensated by Alkermes.
Choose the titration process that best fits your patients’ needs
Titrate gradually to a dose that best fits your patients’ needs based on efficacy and tolerability1
- After starting at 4.5 g per night, you may increase by 1.5 g increments per week, or you may increase more gradually based on efficacy and tolerability
Titrate gradually to a dose that best fits their needs1
- Start on the 4.5 g once per night and then increase by 1.5 per night at weekly intervals to the maximum recommended dosage of 9 g once per night orally
Extended-release LUMRYZ is the first and only single-dose oxybate approved for pediatric use (ages ≥7)1
Select the nearest equivalent dose of LUMRYZ1
- For example, 7.5 g of LUMRYZ is approximately 2 doses of 3.75 g twice-nightly oxybate
Are your patients missing their second dose?
To ensure an appropriate starting dose for patients switching to LUMRYZ, consider asking how frequently they miss the second dose of their current twice-nightly therapy.
Select the nearest equivalent dose of LUMRYZ1
- Because the recommended starting dosage in pediatric patients 7 years and older weighing less than 45 kg (99 lb) cannot be achieved with the available strengths of LUMRYZ, use another sodium oxybate product to initiate treatment. Refer to the Prescribing Information of other sodium oxybate products for the recommended dosage for those products
- Pediatric patients ≥20 kg (44 lb) can be switched to LUMRYZ if they are taking a 4.5 g dose or higher of another oxybate. The dose may be gradually titrated based on efficacy and tolerability
- The maximum recommended dosage for patients 7 years and older weighing 20 kg to <30 kg is 6 g once per night orally
- The maximum recommended dosage for patients 7 years and older weighing 30 kg to <45 kg is 7.5 g once per night orally
- There is insufficient information to provide specific dosing recommendations for patients 7 years and older who weigh less than 20 kg
What might it mean for family and care partners to not wake to administer a middle-of-the-night dose?
For patients new to LUMRYZ
It’s important to let patients know that everybody responds to treatment differently and it may take time to see a difference in their daytime symptoms as their body adjusts to the medicine.
LUMRYZ dosing information
Once-at-bedtime, premeasured packets contain your patient’s full therapeutic dose, supporting consistent dosing1,3
Doses are available in 4.5 g, 6 g, 7.5 g, and 9 g packets.1
LUMRYZ is taken orally as a single dose at bedtime1
- Mix 1 premeasured packet with water1,4*
- If desired, patients can include a calorie-free drink mix or flavored water enhancer, such as Crystal Lite or Mio Flavored Water Enhancer
Each dose contains a blend of immediate- and controlled-release granules1,2,5
- Shake for 60 seconds—expect the granules to not fully dissolve in water* and have a gritty texture with a salty taste5
LUMRYZ should be taken at least 2 hours after eating and when in bed1
- Patients may fall asleep within 5 to 15 minutes of taking their dose without feeling drowsy
- Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use) for full administration instructions.
- *Do not use hot water.4
These instructions are not complete. Download Instructions for Use for complete administration directions.
Information to share with patients as they begin treatment
Support successful patient startsTyler is a real patient, compensated by Alkermes.
Choose the titration process that best fits your patients’ needs
Titrate gradually to a dose that best fits your patients’ needs based on efficacy and tolerability1
- After starting at 4.5 g per night, you may increase by 1.5 g increments per week, or you may increase more gradually based on efficacy and tolerability
Titrate gradually to a dose that best fits their needs1
- Start on the 4.5 g once per night and then increase by 1.5 per night at weekly intervals to the maximum recommended dosage of 9 g once per night orally
Extended-release LUMRYZ is the first and only single-dose oxybate approved for pediatric use (ages ≥7)1
Select the nearest equivalent dose of LUMRYZ1
- For example, 7.5 g of LUMRYZ is approximately 2 doses of 3.75 g twice-nightly oxybate
Are your patients missing their second dose?
To ensure an appropriate starting dose for patients switching to LUMRYZ, consider asking how frequently they miss the second dose of their current twice-nightly therapy.
Select the nearest equivalent dose of LUMRYZ1
- Because the recommended starting dosage in pediatric patients 7 years and older weighing less than 45 kg (99 lb) cannot be achieved with the available strengths of LUMRYZ, use another sodium oxybate product to initiate treatment. Refer to the Prescribing Information of other sodium oxybate products for the recommended dosage for those products
- Pediatric patients ≥20 kg (44 lb) can be switched to LUMRYZ if they are taking a 4.5 g dose or higher of another oxybate. The dose may be gradually titrated based on efficacy and tolerability
- The maximum recommended dosage for patients 7 years and older weighing 20 kg to <30 kg is 6 g once per night orally
- The maximum recommended dosage for patients 7 years and older weighing 30 kg to <45 kg is 7.5 g once per night orally
- There is insufficient information to provide specific dosing recommendations for patients 7 years and older who weigh less than 20 kg
What might it mean for family and care partners to not wake to administer a middle-of-the-night dose?
For patients new to LUMRYZ
It’s important to let patients know that everybody responds to treatment differently and it may take time to see a difference in their daytime symptoms as their body adjusts to the medicine.
I like the dosing packets for LUMRYZ because I don’t have to measure it myself. It allows me to just focus on mixing my dose and not having to measure the right amount of medication.”
-Tyler
Hear what patients have to say about LUMRYZ
Tyler was compensated by Alkermes. Individual results may vary.
References: 1. LUMRYZ® (sodium oxybate for extended-release oral suspension). Prescribing Information. Chesterfield, MO: Avadel Pharmaceuticals. 2. Bogan R, Thorpy MJ, Winkelman JW, Dubow J, Gudeman J, Seiden D. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: phase 1 study in healthy volunteers. Sleep Med. 2022;100:442-447. 3. Seiden D, Tyler C, Dubow J. Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults. Clin Ther. 2021;43(4):672.el-672.e14. 4. LUMRYZ. Instructions for Use. Chesterfield, MO: Avadel Pharmaceuticals; 2025. 5. Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45(6):1-11.
